ACIL
NSE: ACIL
₹00.00
As on 20 August, 2022 | 10:03

Share Price

Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Share Returns

  • Over 1 Month 0%
  • Over 3 Month 0%
  • Over 6 Month 0%
  • Over 1 Year 0%

Key Statistics

Investment Rating

  • Master Rating:
  • Bacil Pharma has an operating revenue of Rs. 1.53 Cr. on a trailing 12-month basis. An annual revenue de-growth of -14% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -315% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 32% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 106 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Financials
  • Indicator
  • Oper Rev Qtr Cr
  • Operating Expenses Qtr Cr
  • Operating Profit Qtr Cr
  • Depreciation Qtr Cr
  • Interest Qtr Cr
  • Tax Qtr Cr
  • Net Profit Qtr Cr

Technicals

EMA & SMA

Current Price
0.18
(0%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 0.18
  • 50 Day
  • 0.18
  • 100 Day
  • 0.17
  • 200 Day
  • 0.15
  • 20 Day
  • 0.18
  • 50 Day
  • 0.18
  • 100 Day
  • 0.17
  • 200 Day
  • 0.15

Resistance and Support

PIVOT
₹0.18
Resistance
  • First Resistance
  • 0.18
  • Second Resistance
  • 0.18
  • Third Resistance
  • 0.18
Support
  • First Resistance
  • 0.18
  • Second Resistance
  • 0.18
  • Third Resistance
  • 0.18
  • RSI
  • 100
  • MFI
  • 61.26

Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • Week
  • 1 Month
  • 6 Month

Result Highlights

Synopsis

BSE-Medical-Generic Drugs

Bacil Pharma belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 6.53 Cr. for the Year ended 31/03/2021. Bacil Pharma Ltd. is a Public Limited Listed company incorporated on 08/05/1987 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24200MH1987PLC043427 and registration number is 043427.
  • Market Cap
  • 3
  • Sales
  • Shares in Float
  • 0.34
  • No of funds
  • Yield
  • Book Value
  • 3
  • U/D Vol ratio
  • 1.7
  • LTDebt / Equity
  • Alpha
  • -0.03
  • Beta
  • 0.43

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 42.67%
  • 42.67%
  • 42.67%
  • Individual Investors
  • 52.9%
  • 52.84%
  • 52.89%
  • Others
  • 4.43%
  • 4.49%
  • 4.44%

Management

  • Name
  • Designation
  • Mr. Shirish Shetye
  • Ind. Non-Executive Director
  • Mr. Lalit Jain
  • Ind. Non-Executive Director
  • Mr. Prakash Shah
  • Director
  • Dr. Sneha Shah
  • Non Executive Woman Director

Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

FAQs

What is Share Price of ?

share price is ₹00 As on 20 August, 2022 | 09:49

Q1FY23